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Abstract
Purpose To investigate whether clinically relevant levels
of epigallocatechin gallate (EGCG, a component of green
tea) or vitamin C (ascorbic acid) could antagonize bortezo-
mib antitumor activity in CWR22 human prostate xenograft
tumors.
Methods The pharmacokinetics (PK) of EGCG and ascor-
bic acid were determined in immunocompromised mice
and compared with concentrations measured in human PK
studies of dietary supplements. Antitumor activity of bort-
ezomib in combination with EGCG or ascorbic acid was
determined using several dosing regimens to evaluate
diVerent target plasma concentrations of EGCG and ascor-
bic acid.
Results Bortezomib dosed twice-weekly at 0.8 mg/kg IV
demonstrated tumor growth inhibition (TGI) of 53.9–
58.9%. However, when combined with EGCG such that the
plasma concentrations of EGCG were >200 M at the time
of bortezomib dosing, all antitumor activity was abrogated
(TGI = ¡17.7%). A lower concentration of EGCG (11–
16 M), which is severalfold higher than measured clini-
cally in humans taking EGCG supplements (0.6–3 M),
was not antagonistic to bortezomib (TGI 63.5%). Pharma-
codynamic studies of proteasome inhibition reXected these
Wndings. Ascorbic acid (40 and 500 mg/kg PO daily) was
evaluated under a similar study design and did not antago-
nize bortezomib antitumor activity (TGI 57.2 and 72.2%).
Conclusions No antagonism of bortezomib is seen in pre-
clinical in vivo experiments, where EGCG or ascorbic acid
plasma concentrations are commensurate with dietary or
supplemental intake. The data suggest that patients receiv-
ing bortezomib treatment do not need to avoid normal die-
tary consumption of green tea, vitamin C-containing foods,
or EGCG or vitamin C dietary supplements.
Keywords Bortezomib · Epigallocatechin gallate · 
Vitamin C · Antagonism · Activity
Introduction
The Wrst-in-class proteasome inhibitor bortezomib (VEL-
CADE®, PS-341) is approved in the United States for the
treatment of patients with multiple myeloma (MM) and for
the treatment of patients with mantle cell lymphoma who
have received at least one prior therapy [1]. In the European
Union, bortezomib is approved in combination with mel-
phalan and prednisone for the treatment of patients with
previously untreated MM who are not eligible for high-
dose chemotherapy with bone marrow transplant, and as
monotherapy for the treatment of progressive MM in
patients who have received at least one prior therapy and
who have already undergone or are unsuitable for bone
marrow transplantation [2]. Bortezomib exerts its antitumor
eVects by reversibly blocking the activity of the 26S protea-
some [3], a critical component of the ubiquitin–proteasome
pathway that is responsible for degrading the majority of
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regulatory intracellular proteins [4]. This inhibition disrupts
multiple downstream signaling pathways in cells, inducing
apoptosis and inhibiting cell-cycle progression, angiogene-
sis, cell adhesion, and proliferation [3, 5].
Bortezomib is a modiWed dipeptidyl boronic acid (Sup-
plemental Fig. 1), which when reconstituted consists of the
mannitol ester in equilibrium with its hydrolysis product,
the monomeric boronic acid [1]. It has been well docu-
mented that boronic acids form tight but reversible bonds
with molecules possessing a diol group [6]. This reaction
suggests that the activity of bortezomib (and other boronic
acid-containing proteasome inhibitors) may be compro-
mised by the presence of 1,2-diol-containing compounds
such as epigallocatechin gallate (EGCG; Supplemental
Fig. 1), a component of green tea, and vitamin C (ascorbic
acid; Supplemental Fig. 1) [7–9], the hypothesis being that
the latter compounds form complexes with the boronic acid
moiety and thus prevent proteasome binding and inhibition.
Data from in vitro studies have indicated that high con-
centrations of EGCG and vitamin C have the potential to
aVect the cytotoxicity of bortezomib. Golden et al. demon-
strated that EGCG at concentrations of 2.5 M and higher
antagonized the cytotoxic eVect of 10 nM bortezomib on
several MM cell lines [8]. In a glioblastoma cell line,
20 M EGCG blocked proteasome inhibition by 20 nM
bortezomib and prevented downstream events including
accumulation of ubiquitinated proteins, endoplasmic reticu-
lum stress, and apoptosis [8]. By evaluating six proteasome
inhibitors with diVerent chemical structures, Golden et al.
demonstrated that EGCG antagonizes proteasome inhibi-
tors containing boronic acid (bortezomib, MG-262, and PS-
IX), but has no eVect on proteasome inhibitors lacking
boronic acid (MG-132, PS-I, and nelWnavir) [8]. This pro-
vides evidence that the direct chemical interaction of
EGCG with the boronic acid-containing compounds is
responsible for the antagonism, rather than placing the
antagonism downstream of proteasome inhibition. Similar
in vitro experiments identiWed comparable reductions in
bortezomib activity when human cell lines were treated
with bortezomib and ascorbic acid [7,  9]. For example,
30 M ascorbic acid partially antagonized the activity of 5
and 10 nM bortezomib on RPMI8226 cells, while 250 M
ascorbic acid showed nearly complete antagonism of 5–
10 nM bortezomib [7]. Thus, as with EGCG, high concen-
trations of ascorbic acid were required for antagonism.
The in vitro experimental conditions, characterized by
the constant presence of bortezomib for 48–72 h in cell cul-
ture, are quite diVerent from in vivo conditions. Pharmaco-
kinetic studies in human plasma indicate that bortezomib
displays a rapid initial distribution phase [10–12], with
plasma concentrations dropping more than 10-fold within
an hour post-dose [12]. This results in a narrow time win-
dow for any potential EGCG:bortezomib or EGCG:ascorbic
acid complex formation to occur in the plasma, and cautions
against direct application of the in vitro results to the clinical
use of bortezomib.
In vivo studies in mouse xenograft models of human
MM have also suggested that oral administration of EGCG
at 25 or 50 mg/kg and vitamin C at 40 mg/kg/day inhibits
the antitumor eVects of bortezomib dosed intraperitoneally
(i.p.) at 0.5 mg/kg and intravenously (IV) at 0.1 mg/kg,
respectively [8, 9]. The Wndings led the authors to conclude
that patients receiving bortezomib treatment should avoid
consuming green tea or vitamin C [8, 9], both of which
have purported beneWts for patients undergoing cancer
treatment. However, others have questioned the validity of
the recommendation to avoid green tea, given the high con-
centration of EGCG required for antagonism of bortezomib
in cultured cells, and the actual concentrations of EGCG
and bortezomib determined in human pharmacokinetic
studies [13].
Further evidence is clearly needed in order to provide
deWnitive recommendations on EGCG or vitamin C con-
sumption for patients receiving bortezomib. We therefore
set out to better deWne the concentrations of EGCG and
bortezomib showing antagonist eVects in cultured cells. We
also wanted to determine the doses of EGCG and vitamin C
and, for EGCG, a route of administration (oral [PO], subcu-
taneous [SC], or intravenous [IV]), in mice that resulted in
plasma concentrations above the ranges of those measured
in human pharmacokinetic studies of EGCG and vitamin C
dietary supplements. Oral dosing of EGCG in mice has pre-
viously been investigated [14] and results in lower maximal
plasma concentrations of EGCG than oral dosing in
humans [15, 16]. In humans taking 800 mg of EGCG sup-
plements (equivalent to the amount of EGCG in approxi-
mately eight cups of green tea), the maximal plasma
concentration was approximately 3 M (1,522 ng/ml) when
EGCG was taken after fasting and approximately 0.6 M
(294 ng/ml) when the supplements were taken with food
[15]. In contrast, oral dosing of 50 and 80 mg/kg in mice
resulted in maximal plasma concentrations of only 0.06–
0.28 M [14, 17]. Therefore, alternate methods of dosing in
mice (SC and IV) were used to investigate the eVects of
EGCG in a higher concentration range that could be
achieved in people taking EGCG supplements. For vitamin
C, oral dosing in mice provides a reasonable match to oral
dosing in humans in terms of the maximal concentrations,
which have been reported to be approximately 150 M fol-
lowing an oral dose of 1,250 mg [18].
Using this information, we investigated whether clini-
cally relevant plasma concentrations of EGCG or vitamin C
could antagonize the antitumor activity of bortezomib in
CWR22 human prostate xenograft tumors, a well-validated
bortezomib-responsive xenograft model in immunocom-
promised mice [19, 20]. Although this is not a xenograftCancer Chemother Pharmacol (2011) 68:1145–1154 1147
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model of MM, it is a suitable model for testing the hypothe-
sis that a concentration-dependent interaction of bortezo-
mib and 1,2-diol-containing compounds in the plasma can
antagonize bortezomib activity by preventing its binding
and inhibition of the proteasome in the target tumor tissue.
Materials and methods
In vitro bortezomib–EGCG combination studies
Serial dilutions of bortezomib (Millennium Pharmaceuti-
cals, Inc., Cambridge, MA) (1:1.5) and EGCG (Sigma–
Aldrich, St Louis, MO) (1:3) in RPMI growth media were
added to a 384-well plate to create duplicate combination
matrices in each plate; 6,000 RPMI-8226 cells were added
to each well. After 48 h, cell viability was determined by
ATP luminescence (Perkin-Elmer, Waltham, MA) using a
Leadseeker imager (GE Life Sciences, Piscataway, NJ).
Plotted data represent the average of six points (three
plates).
Pharmacokinetic studies
EGCG and vitamin C (Sigma–Aldrich) were prepared fresh
for all studies, and the appropriate amount of each com-
pound was formulated with 0.9% saline.
For the EGCG studies, naïve female nude or naïve male
CB-17 severe combined immunodeWcient (SCID) mice,
aged 5–8 weeks, from Charles River Laboratories, Wil-
mington, MA, received »0.1 ml doses of EGCG adminis-
tered PO (50 mg/kg), IV (50 and 100 mg/kg), or SC
(50 mg/kg). Animals were dosed on the basis of an average
body weight of 25 grams. For the vitamin C studies, male
CB-17 SCID mice bearing CWR22 tumors (average body
weight of 21 g) received approximately 0.1 ml doses of
vitamin C administered PO (40 and 500 mg/kg). In all
experiments described in this report, mice had access to
food and water ad libitum and were housed and handled in
accordance with the Guide for the Care and Use of Labora-
tory Animals, and Millennium Institutional Animal Care
and Use Committee Guidelines.
Animals were anesthetized with CO2, and whole blood
samples (»0.5 ml) were collected via cardiac puncture
using a 25-gauge needle attached to a 1-ml syringe
(Becton–Dickinson [BD], Franklin Lakes, NJ). Samples for
EGCG quantiWcation were collected from each animal at 5,
15, and 30 min and at 1, 2, 4, 8, 24, and 48 h post-dose.
Samples for vitamin C quantiWcation were collected from
each animal at 0.5, 1, 2, 4, and 6 h post-dose. Whole blood
samples for the EGCG or vitamin C studies were trans-
ferred to BD Microtainer® ethylenediaminetetraacetic acid
(EDTA) blood collection tubes or lithium heparin blood
collection tubes, respectively, then centrifuged at 10,000 rpm
for 10 min at approximately 4°C. Ascorbic acid/EDTA or
10% metaphosphoric acid (MPA; Sigma–Aldrich) buVer
solutions were added to the harvested plasma samples (1:1
ratio) to stabilize the EGCG or vitamin C, respectively,
before tubes were frozen on dry ice, then stored at ¡80°C
until analysis.
Concentrations of EGCG in prepared plasma samples
were quantiWed using liquid chromatography with tandem
mass spectrometry (LC/MS/MS). The LC/MS/MS system
consisted of an API 4000 triple quadrupole mass spectrom-
eter (AB Sciex, Foster City, CA) equipped with an Agilent
1100 high-performance liquid chromatography (HPLC)
system (Agilent Technologies, Inc, Santa Clara, CA). Ana-
lytes were eluted from a Luna C 18 4.6 £ 50 mm column
(Phenomenex, Torrance, CA) using a linear gradient pro-
gram consisting of 0.1% (volume-to-volume ratio [v:v])
formic acid (FA) (EMD Chemicals, Inc, Gibbstown, NJ) in
water (mobile phase A) and 0.1% (v:v) FA in acetonitrile
(mobile phase B) at a Xow rate of 1.0ml/min. EGCG was
detected under a negative ion spray mode using the multi-
ple reaction monitoring (MRM) of a mass transition pair at
mass-to-charge ratio (m/z) of 457.2/169.0 for EGCG.
The LC/MS/MS system used to determine vitamin C
concentrations in prepared plasma consisted of a AB
SCIEX QTRAP® 5500 mass spectrometer (AB Sciex, Fos-
ter City, CA) equipped with an Shimadzu Prominence
high-performance liquid chromatography (HPLC) system
(Shimadzu ScientiWc Instruments, Columbia, MD). Ana-
lytes were eluted from a Luna 5 M HILIC 200 Å,
150 £ 4.6 mm column (Phenomenex, Torrance, CA) using
an isocratic gradient (mobile phase B 30%) at a Xow rate of
2 ml/min. Both mobile phases were prepared according to
Phenomenex product guides using three solvent systems:
solvent A was acetonitrile (EMD chemicals, Gibbstown,
NJ, USA); solvent B was 100 mM ammonium acetate
(Sigma–Aldrich), pH 5.8; and solvent C was pure water
(Honeywell, Morristown, NJ). Mobile phase A consisted of
the solvent ratio mixture A:B:C = 90:5:5. Mobile phase B
consisted of the solvent ratio mixture A:B:C = 50:45:5.
Ascorbic acid was detected under a negative ion spray
mode using the MRM of a mass transition pairs at m/z of
175.0/114.8 for vitamin C.
In vivo antitumor activity studies
Male CB-17 SCID mice aged 5–8 weeks were inoculated
SC via trocar in the Xank with CWR22 human prostate
tumor fragments. Tumor growth was monitored biweekly
(BIW) using calipers, and the mean tumor volume was cal-
culated using the formula (0.5 £ [length £ width2]). When
the mean tumor volume reached approximately 150–
250 mm3, animals were randomized into treatment groups1148 Cancer Chemother Pharmacol (2011) 68:1145–1154
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(n = 9/group). Dosing regimens were selected using the
pharmacokinetic proWles established for EGCG and vita-
min C to obtain several target plasma concentrations of
EGCG and vitamin C to evaluate for antagonism of bort-
ezomib. In the study with IV administration of EGCG, mice
were dosed BIW for 7 doses with vehicle (0.9% saline) IV,
bortezomib 0.8 mg/kg IV, EGCG 50 mg/kg IV, or a combi-
nation of bortezomib 0.8 mg/kg IV and EGCG 50 mg/kg
IV. In the combination group, EGCG was dosed Wrst and
bortezomib was dosed approximately 2 min after EGCG
administration. In the study with SC administration of
EGCG, mice received vehicle, bortezomib (0.8 mg/kg IV
BIW) alone, EGCG (50 mg/kg SC BIW) alone, or a combi-
nation of bortezomib (0.8 mg/kg IV BIW) and EGCG
(50 mg/kg SC BIW) for seven doses. There were three
diVerent dosing regimens for the combination groups. In
the Wrst two combination groups, EGCG was dosed Wrst
and bortezomib was dosed approximately 30 or 60 min
after EGCG administration. In the third combination group,
bortezomib was dosed Wrst and EGCG was dosed approxi-
mately 60 min after bortezomib administration.
For the vitamin C studies, mice were dosed with vehicle
(0.9% saline IV BIW), ascorbic acid (40 or 500 mg/kg PO
QD) alone, bortezomib (0.8 mg/kg IV BIW) alone, or a
combination of ascorbic acid (40 or 500 mg/kg PO QD)
and bortezomib (0.8 mg/kg IV BIW) for 22 days. In the
combination groups, bortezomib was administered 1 h after
ascorbic acid administration.
Antitumor activity was determined by calculating the
percent tumor growth inhibition (TGI; [mean tumor volume
of the control group—mean tumor volume of a treated
group]/mean tumor volume of the control group) on days
22 or 25. Combination treatments were also analyzed at the
end of study to evaluate antagonism between EGCG and
bortezomib.
Pharmacodynamic studies
Activity of the 20S proteasome in blood and xenograft
tumors was measured by an enzymatic assay, and down-
stream consequences of proteasome inhibition in CWR22
tumors were detected as the accumulation of proteasome
substrates and the upregulation of markers of endoplasmic
reticulum stress and the unfolded protein response, includ-
ing GADD34 and ATF3, as previously described [20]. For
phospo--catenin (Ser33/Ser37/Thr41), primary antibody
was Cell Signaling #9561.
Statistical analysis
The diVerences in the tumor growth trends over time
between pairs of treatment groups were assessed using lin-
ear mixed eVects regression models as previously described
[20]. Drug combinations were assessed for synergy or
antagonism using observed AUC (area under the curve)
values. The change in AUC (AUC) relative to the control
was calculated for both single-agent treatment groups and
the combination group. The interaction between the two
compounds was then assessed by comparing the AUC
observed in the combination group to the sum of the
changes observed in both single-agent groups. Statistically
signiWcant negative (less than zero) synergy scores indi-
cated a synergistic combination. Statistically signiWcant
positive (greater than zero) synergy scores indicated a
sub-additive or antagonistic combination. Scores of zero
and scores that were not statistically signiWcant were con-
sidered additive (neither synergistic nor antagonistic). All
P values < 0.05 were considered statistically signiWcant.
Results
In vitro combination experiments with EGCG
Experiments in the RPMI8226 MM cell line in a matrix for-
mat (Fig. 1) showed that a substantial shift in the potency of
bortezomib in cell viability experiments required a high
concentration of EGCG (>1 M). An EGCG concentration
of 1.3 M caused a minor shift in the IC50 of bortezomib
from 6.1 to 9.3 nM, whereas 3.8 M EGCG caused a 2.5-
fold increase in the IC50 of bortezomib to 15 nM (Fig. 1).
At the highest concentration of bortezomib used in these
experiments (40 nM), EGCG concentrations ¸11 M were
required to even partially overcome the cytotoxicity of
bortezomib. EGCG 100 M was cytotoxic on its own, and
so antagonism of bortezomib could not be evaluated at this
concentration.
Pharmacokinetic experiments with EGCG
A single oral dose of EGCG 50 mg/kg in naïve female nude
mice resulted in a mean plasma EGCG Cmax value of 76.3
nM. Mean plasma Tmax was 30 min (Fig. 2a). These data
are consistent with previously published Wndings in which
50 mg/kg EGCG administered intragastrically resulted in a
plasma concentration of approximately 60 nM at 50 min
[17].
Because the EGCG concentrations achieved by oral dos-
ing were so low compared with the levels detected in
human pharmacokinetic studies of EGCG supplements, we
characterized IV and SC dosing routes of EGCG in mice. In
two studies in naïve male CB17 SCID mice, SC EGCG
50 mg/kg resulted in mean Cmax values of 33.7 and
26.0 M, with a mean plasma Tmax of 5 min in both studies.
EGCG plasma concentrations at 30 min post-dose were
16.2 and 11.3 M, respectively, and dropped to 8.4 andCancer Chemother Pharmacol (2011) 68:1145–1154 1149
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3.9 M by 1 h, and 2.8 and 2.5 M by 2 h, respectively
(Fig. 2b). IV administration of EGCG at 50 and 100 mg/kg
in naïve male CB17 SCID mice resulted in higher mean
plasma levels of EGCG than SC dosing, producing mean
measured plasma Cmax values of 224 and 240 M (Fig. 2c).
The earliest IV sampling times in these studies were 2 and
5 min, respectively. Plasma levels of EGCG declined rap-
idly after IV dosing and were <20 M within 30 min of
dosing.
Antitumor activity in EGCG/bortezomib combination 
experiments
Several target plasma concentrations of EGCG were evalu-
ated for antagonism of bortezomib; data from the pharma-
cokinetic studies provided information on EGCG plasma
concentrations at various time points post-SC/IV adminis-
tration at which time bortezomib was subsequently admin-
istered (Table 1). The eVect of dosing bortezomib Wrst,
followed by SC EGCG dosing 1 h later, was also investi-
gated. The pharmacokinetic proWle of bortezomib in mice
has a rapid distribution phase, as is the case in humans [20].
Therefore, by 1 h post-dose, very little bortezomib is pres-
ent in the plasma to potentially interact with EGCG.
Single-agent bortezomib 0.8 mg/kg IV demonstrated a
TGI of 53.9–58.9% versus the control group (Fig. 3;
P < 0.001) in CWR22 xenograft-bearing mice, which was
consistent with reports of signiWcant antitumor activity seen
in previous studies [19, 20]. IV administration of EGCG
50 mg/kg alone did not show any antitumor activity versus
control (Fig. 3a; TGI = ¡15.3%; P >0 . 0 5 ) .  E G C G  5 0m g /
kg IV administered 2 min prior to bortezomib 0.8 mg/kg IV
resulted in no antitumor activity (TGI = ¡17.7%, P >0 . 0 5
versus control), demonstrating antagonism between EGCG
and bortezomib when EGCG levels were >200 M at the
time of bortezomib dosing (Fig. 3a). In studies of SC
EGCG administration (Fig. 3b), 50 mg/kg EGCG as a sin-
gle agent did not result in antitumor activity (TGI = 3.6%;
P > 0.05 versus control). However, SC EGCG 50 mg/kg
followed 30 or 60 min later by bortezomib 0.8 mg/kg IV
exhibited signiWcant antitumor activity with a TGI of 63.5
and 46.3%, respectively, compared with controls (P < 0.001).
Similarly, bortezomib 0.8 mg/kg IV followed 60 min later
by SC EGCG 50 mg/kg also exhibited signiWcant antitumor
activity versus controls (TGI = 61.3%; P <0 . 0 0 1 ) .  T h u s ,
there was no antagonism between EGCG and bortezomib
when EGCG levels were 16 M and lower at the time of
bortezomib dosing, or when bortezomib was administered
1 h before EGCG (P > 0.05 versus controls for each combi-
nation). A repeat of this study conWrmed these Wndings
(data not shown).
Pharmacodynamic eVects of EGCG/bortezomib 
combination treatment
Pharmacodynamic studies were conducted to determine
whether EGCG showed a concentration-dependent ability to
antagonize bortezomib-induced proteasome inhibition in
blood or tumor tissue. Based on previous PD studies with
bortezomib, a time point of 4 h post-dosing was chosen for
sample collection. An enzymatic assay for proteasome activ-
ity and Western blot-based assays for downstream conse-
quences of proteasome inhibition (accumulation of the
proteasome substrate phospho--catenin [Ser33/Ser37/Thr41]
and upregulation of ATF3 and GADD34, markers of the
unfolded protein response) were both employed. No inhibi-
tion of proteasome activity compared with vehicle controls
was seen with EGCG 50 mg/kg IV alone (Fig. 4a). Four
hours after IV administration of bortezomib 0.8 mg/kg, mean
20S proteasome inhibition was 44% in blood and 52% in
tumor. This proteasome inhibition was blunted by the combi-
nation of EGCG 50 mg/kg IV followed 2 min later by bort-
ezomib 0.8 mg/kg IV, which resulted in only 25 and 33%
proteasome inhibition in blood and tumor, respectively, at 4 h
post-administration. These results indicate partial antagonism
of proteasome inhibition by IV dosing of EGCG, which is fur-
ther reXected in the analysis of downstream pharmacody-
namic markers and ultimately in the antagonism of antitumor
activity in this combination regimen. Bortezomib 0.8 mg/kg
IV results in elevated levels of phospho--catenin, GADD34,
Fig. 1 In vitro antagonism of 
bortezomib by high concentra-
tions of EGCG in RPMI-8226 
cultured cells. a Matrix format 
for luminescent ATP-lite cell 
viability assay. b Data in graph 
represent an average of six 
points (three plates with dupli-
cates on each plate)1150 Cancer Chemother Pharmacol (2011) 68:1145–1154
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and ATF3 compared with vehicle controls (Fig. 4b). EGCG
50 mg/kg IV on its own does not change levels of these phar-
macodynamic markers. However, EGCG is able to prevent
Fig. 2 Pharmacokinetics of EGCG in mice following a oral,
b subcutaneous, and c intravenous dosing
Table 1 EVect of varying administration route and time between EGCG and bortezomib doses on plasma concentration of EGCG at the time of
bortezomib dosing
BIW, twice-weekly; IV, intravenous; SC, subcutaneous
Treatment Interval between EGCG 
and bortezomib 
dosing (min)
Projected plasma concentration 
of EGCG at the time of 
bortezomib dosing (M)
50 mg/kg SC EGCG BIW + 0.8 mg/kg IV bortezomib BIW 60 4–8
50 mg/kg SC EGCG BIW + 0.8 mg/kg IV bortezomib BIW 30 11–16
50 mg/kg IV EGCG BIW + 0.8 mg/kg IV bortezomib BIW 2 224
Fig. 3 Evaluation of EGCG antagonism of bortezomib activity in
CWR22 xenograft-bearing mice with EGCG administered
a intravenously or b subcutaneouslyCancer Chemother Pharmacol (2011) 68:1145–1154 1151
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the elevation of phospho--catenin, GADD34, and ATF3 in
tumors from mice dosed with the combination schedule of
EGCG 50 mg/kg IV followed 2 min later by bortezomib
0.8 mg/kg IV.
The antagonistic eVect of EGCG on pharmacodynamic
markers of proteasome inhibition appears to be concentra-
tion dependent, because EGCG 50 mg/kg SC followed 30
or 60 min later by bortezomib 0.8 mg/kg IV had little or no
Fig. 4 Antagonism of the phar-
macodynamic eVects of 
bortezomib with intravenous 
administration (a, b)b u t  n o t  
subcutaneous administration 
(c, d) of EGCG demonstrates 
concentration-dependence of 
antagonism. a, c Blood and 
tumor proteasome inhibition 4 h 
post-dose measured by enzy-
matic assay of 5 speciWc 
activity. b, d Western blot of 
xenograft tumors to measure 
proteasome substrate [phospho-
-catenin (Ser33/Ser37/Thr41)] 
and pathway markers of ER 
stress response (ATF3 and 
GADD34) in the same tumor 
samples used in a and c1152 Cancer Chemother Pharmacol (2011) 68:1145–1154
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antagonistic eVect on proteasome inhibition in blood or
tumor (Fig. 4c). In this experiment, bortezomib 0.8 mg/kg
IV alone resulted in mean proteasome inhibition of 59% in
blood, compared with 54 and 56% using the combination
schedules, respectively. Proteasome inhibition in tumor
was >50% in all groups, consistent with the Wndings from
the antitumor activity studies. ReXecting these results,
phospho--catenin, GADD34, and ATF3 elevations were
detected in all groups, with no substantial diVerence
between the single-agent bortezomib and EGCG/bortezo-
mib combination groups (Fig. 4d).
Pharmacokinetic experiments with ascorbic acid
Levels of endogenous ascorbic acid measured in naïve or
CWR22 tumor-bearing male CB-17 SCID mice were in the
range 48.3–59.2 M, consistent with previously reported
mouse [21] and human [9, 18, 22] endogenous plasma lev-
els. Oral dosing of ascorbic acid at 40 and 500 mg/kg
results in the elevation of plasma concentrations above the
endogenous level by 30 min post-dose, and the elevated
level is maintained for at least 6 h. Following a single oral
dose of ascorbic acid 40 mg/kg, mean Cmax was 72.8 M in
the tumor-bearing mice at Tmax of 4 h (Fig. 5a). Following a
single oral dose of ascorbic acid 500 mg/kg, mean Cmax was
193 M at Tmax of 2 h (Fig. 5a). The pharmacokinetic pro-
Wle in nontumor-bearing mice was similar (data not shown).
Antitumor activity in bortezomib/ascorbic acid 
combination treatment
Based on pharmacokinetic Wndings, a 1 h interval between
ascorbic acid and bortezomib administration was selected
for antitumor activity experiments. The plasma levels at
this time point following the 500 mg/kg dose are in line
with human ascorbic acid exposures in subjects who had
taken 1–1.25 g of dietary supplements [9, 18].
Ascorbic acid 40 or 500 mg/kg alone did not exhibit any
antitumor activity (TGI = ¡24.4% and ¡15.5%, respec-
tively; P > 0.05 versus controls), while bortezomib 0.8 mg/
kg IV alone had signiWcant antitumor activity compared
with controls (TGI = 62.8%; P < 0.001) (Fig. 5b). Ascorbic
acid 40 or 500 mg/kg in combination with bortezomib also
exhibited signiWcant antitumor activity compared with con-
trols (TGI = 57.2 and 72.2%, respectively; P < 0.001). No
antagonism was seen between ascorbic acid and bortezo-
mib in any of the combination groups (P > 0.05).
Discussion
The  Wndings from our studies reported herein provide
important new evidence regarding the potential eVect of
EGCG or vitamin C consumption on bortezomib activity in
patients receiving therapy. Our results demonstrate that no
antagonistic interactions between EGCG and bortezomib,
or ascorbic acid and bortezomib, are seen in preclinical
models at plasma concentrations of EGCG and ascorbic
acid commensurate with human dietary or supplemental
intake.
Our in vitro EGCG experiments were intended to char-
acterize the minimum concentration at which antagonism
was detected. Golden et al. demonstrated that the activity of
bortezomib was aVected by EGCG in vitro, but the lowest
EGCG concentration used was 2.5 M [8]. Our studies
showed that EGCG concentrations of up to 0.4 M had no
impact on the cytotoxicity of bortezomib in RPMI8226
cells. The IC50 of bortezomib did double (from 7 to 15 nM)
with an increase in EGCG concentration from 0.4 to
Fig. 5 a Pharmacokinetics of orally administered ascorbic acid in
male CB-17 SCID mice and b the eVect of concomitant administration
of ascorbic acid on the antitumor activity of bortezomib in CWR22
xenograft-bearing miceCancer Chemother Pharmacol (2011) 68:1145–1154 1153
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3.8 M, indicating partial antagonism. Importantly, even at
an EGCG concentration of 3.8 M, there was no antago-
nism of 40 nM bortezomib. Antagonism of 40 nM bortezo-
mib only became evident once EGCG concentrations
reached 11 M and above. Thus, substantial changes in the
in vitro potency of bortezomib only occurred at micromolar
concentrations of EGCG. The maximal plasma concentra-
tion of EGCG measured in people taking 800 mg supple-
ments (equivalent to the amount of EGCG in eight cups of
green tea) is approximately 3 M, but this is reached only
when the supplements are taken after fasting [15, 16].
Replicating these high concentrations in mice required
IV or SC dosing of EGCG. Maximal EGCG concentrations
after IV and SC dosing at 50 mg/kg were much higher than
human plasma Cmax values, at >200 and >25 M, respec-
tively, and plasma concentration remained higher than
3 M for up to almost 2 h. In contrast, oral dosing at 50 mg/
kg, the dose used in a previous study evaluating EGCG
antagonism of bortezomib [8], resulted in maximal plasma
concentrations of <0.1 M in our studies and in other
mouse pharmacokinetic studies [17]. These pharmacoki-
netic Wndings informed the selection of several dosing regi-
mens providing a range of EGCG plasma concentrations
for investigation of antagonistic eVects on bortezomib anti-
tumor activity. Data from our experiments in CWR22
xenograft-bearing mice showed signiWcant antitumor activ-
ity with single-agent bortezomib that was consistent with
previous studies [19, 20], with this activity being antago-
nized by the presence of EGCG at very high concentrations
(224 M, achieved via IV administration 2 min before bort-
ezomib dosing). This concentration is approximately 80-
fold higher than the 3 M maximal concentration observed
in human pharmacokinetic studies of EGCG dietary supple-
ments taken while fasting. In contrast, results from studies
using SC administration of EGCG, in which EGCG was
present at concentrations up to 16 M at the time of
bortezomib dosing, demonstrated that EGCG was not
antagonistic to bortezomib even at concentrations up to
4- to 5-fold higher than maximal concentrations of EGCG
observed in human pharmacokinetic studies [15, 16].
Our pharmacodynamic analyses of proteasome inhibi-
tion by bortezomib in the presence and absence of EGCG
showed Wndings consistent with the results of the antitumor
activity studies, with antagonism of pharmacodynamic
eVects observed only with the very high concentrations of
EGCG (>200 M) achieved with the combination of
EGCG 50 mg/kg IV followed 2 min later by bortezomib
0.8 mg/kg IV. We hypothesize that ester formation in blood
at high EGCG concentrations prevents distribution of free
bortezomib to the tumor and therefore prevents proteasome
inhibition. The markers reXecting the downstream con-
sequences of proteasome inhibition (accumulation of
phospho--catenin, GADD34, and ATF3) may be the most
reliable pharmacodynamic markers in this context, because
they cannot be inXuenced by ex vivo changes in the
EGCG–bortezomib complex. For example, if EGCG–bort-
ezomib ester were present in a blood sample but hydrolyzed
during sample processing, then newly liberated bortezomib
could inhibit the proteasome ex vivo, thus resulting in an
overestimate of proteasome inhibition. However, the con-
sistent results of our multiple assays tracking diVerent
stages in the proteasome inhibition pathway, from enzyme
inhibition to endoplasmic reticulum stress response, pro-
vide conWdence in the robustness of our Wndings.
Our studies with ascorbic acid and bortezomib found no
antagonistic eVects on bortezomib antitumor activity at
plasma concentrations of ascorbic acid recorded in pharma-
cokinetic studies in humans taking oral vitamin C supple-
ments [9, 18]. While studies in cell culture have indicated
that high concentrations of ascorbic acid (250 M) can
almost completely antagonize the ability of 5–10 nM bort-
ezomib to inhibit the proteasome and kill cells [7, 9], in
vivo plasma concentrations of up to 200 M did not aVect
the antitumor activity of bortezomib in our xenograft exper-
iment. This highlights the diYcultly of extrapolating from
in vitro results and the importance of evaluating drug inter-
actions in a physiologically relevant system.
In conclusion, while the Wndings of our studies are con-
sistent with a concentration-dependent antagonism of the
antitumor activity of bortezomib by EGCG in CWR22
xenograft-bearing mice, antagonism is only seen when very
high levels of EGCG (80-fold greater than those reported in
human subjects taking EGCG supplements while fasting)
are present at the time of bortezomib dosing. Plasma con-
centrations of EGCG and ascorbic acid reported in human
subjects taking EGCG or vitamin C supplements show no
antagonism to the antitumor activity of bortezomib in
CWR22 xenograft-bearing mice, and therefore there
appears no need for patients receiving bortezomib therapy
to avoid normal dietary consumption of green tea, vitamin
C-containing foods, or EGCG or vitamin C dietary supple-
ments.
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